Cruz M N, Stewart G, Rosenberg N
Department of Pediatrics, Children's Hospital of Michigan, Detroit 48201, USA.
Pediatrics. 1995 Aug;96(2 Pt 1):220-3.
Recent studies have demonstrated that a single intramuscular injection of dexamethasone (0.6 mg/kg) shortens the duration and severity of illness in hospitalized patients with acute viral laryngotracheitis (croup). Our objective was to determine if dexamethasone has a role in the outpatient management of patients with acute viral croup of moderate severity.
Patients, 6 months to 5 years of age, who came to the emergency department (ED) with acute viral croup, a croup score of at least 2 (range 0 to 17), and a disposition of discharge were randomized in a double-blind fashion to receive a single intramuscular injection of dexamethasone, 0.6 mg/kg, or an equal volume of normal saline before discharge from the ED. Patients were excluded if they had any structural abnormalities, had received any steroids in the preceding 24 hours, or if they required beta-agonist therapy, more than one racemic epinephrine treatment, or hospitalization. Patients were followed up by telephone 24 hours and 7 to 10 days after discharge to determine whether additional medical attention was sought for perceived lack of improvement or worsening of symptoms. Secondary outcome included the parents' perception of how the child was doing at 24 hours, based on a 4-point ordinal scale: worse (1), same (2), improved (3), symptoms resolved (4), and the number of days it took for complete recovery.
Of the 38 patients comprising the study group, 19 received dexamethasone. The median age was 19 months (range 6 to 66 months), and median pretreatment croup score was 3 (range 2 to 5) for both groups. The number of patients requiring racemic epinephrine was similar in both groups. Five patients sought additional medical attention within 48 hours. Four of the five patients had received placebo (21% of the placebo group) and one had received dexamethasone (5% of the steroid group) (not statistically significant). At the 24-hour telephone follow-up, significantly more patients in the dexamethasone group had a score consistent with improvement compared with placebo (84% vs 42%, P = .003). There was no difference in the number of days for symptoms to completely resolve between the two groups.
The use of dexamethasone in the outpatient management of viral croup was associated with a reduction in severity of illness within 24 hours after treatment. Patients with viral croup of moderate severity should be considered as candidates for the use of dexamethasone before discharge from the ED.
近期研究表明,单次肌内注射地塞米松(0.6毫克/千克)可缩短急性病毒性喉气管炎(哮吼)住院患者的病程并减轻病情严重程度。我们的目的是确定地塞米松在中度急性病毒性哮吼患者的门诊治疗中是否起作用。
年龄在6个月至5岁之间、因急性病毒性哮吼前来急诊科就诊、哮吼评分至少为2分(范围为0至17分)且拟出院的患者,在急诊科出院前以双盲方式随机接受单次肌内注射0.6毫克/千克地塞米松或等量生理盐水。如果患者有任何结构异常、在过去24小时内接受过任何类固醇治疗,或者需要使用β受体激动剂治疗、接受过不止一次消旋肾上腺素治疗或住院治疗,则将其排除。出院后24小时以及7至10天通过电话对患者进行随访,以确定是否因感觉症状未改善或恶化而寻求额外医疗护理。次要结局包括父母根据4分序数量表对孩子在24小时时状况的看法:更差(1分)、相同(2分)、改善(3分)、症状缓解(4分),以及完全康复所需的天数。
研究组的38例患者中,19例接受了地塞米松治疗。两组的中位年龄均为19个月(范围为6至66个月),治疗前哮吼评分中位数均为3分(范围为2至5分)。两组中需要消旋肾上腺素治疗的患者数量相似。5例患者在48小时内寻求了额外医疗护理。这5例患者中有4例接受了安慰剂(占安慰剂组的21%),1例接受了地塞米松(占类固醇组的5%)(无统计学意义)。在24小时电话随访时,与安慰剂组相比,地塞米松组中症状改善的患者比例显著更高(84%对42%,P = 0.003)。两组症状完全缓解所需的天数没有差异。
在门诊治疗病毒性哮吼时使用地塞米松与治疗后24小时内病情严重程度降低有关。中度急性病毒性哮吼患者在急诊科出院前应考虑作为使用地塞米松的对象。